Report Options

Date published 
July 2011

Page Count
214

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 



Autoimmune Diseases - Pipelines for Crohn’s Disease, Multiple Sclerosis and Rheumatoid Arthritis - Overview

Part of the Insight Update Series 

Author: Lucy Sannes, PhD, MBA

Report Brochure CoverThis report focuses on current and pipeline candidate therapeutics and their respective targets for three autoimmune diseases and answers such questions as:

 

  • Who are the companies with active development programs for these diseases?
  • Which targets are actively being investigated and what new targets are coming forward?
  • Who has candidates in active Phase III and Phase II clinical trials?
  • What does the overall target activity map, from launched drug to preclinical research candidates look like?
  • Where are next generation biological therapeutics found across these three diseases?
  • Are small molecules a significant portion of the development activity?

 

Autoimmune Diseases: Pipelines for Crohn’s Disease, Multiple Sclerosis and Rheumatoid Arthritis describes pipeline activities across these three diseases. We report on the:

  • Development pipelines for each disease providing information on company and licensee involvement.
  • Active Phase III and Phase II clinical trials and provide study completion dates.
  • Targets involved across the spectrum of launched and preclinical activities. 
  • Competition among companies developing therapeutics targeting the same or related physiology. 
  • Pace of development activities across these three diseases.
  • Small or specialty companies with innovative therapy development programs.